FindTrial
Sign In

Oxaliplatine Accord 5 mg/ml concentraat voor oplossing voor infusie

DRUG6 trials

Sponsors

AstraZeneca AB, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Catharina Ziekenhuis Stichting, Stichting Amsterdam UMC, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Conditions

Advanced Biliary Tract CancersColorectal liver metastasesIntrahepatic cholangiocarcinomaPancreatic cancerperitoneal dissemination in stomach cancer patients

Phase 1

Hepatic arterial infusion versus intravenous oxaliplatin in a safety, feasibility, and pharmacokinetic study of liver-dominant malignancies – ARTEMIS OXYS-I trial
Not yet recruitingCTIS2026-527509-39-01
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Colorectal liver metastases, Intrahepatic cholangiocarcinoma
Target: 13Updated: 2026-10-07

Phase 2

Personalized dosing of FOLFIRINOX in pancreatic cancer patients: a phase-2 pharmacokinetic, safety and feasibility trial
RecruitingCTIS2024-510576-21-00
Catharina Ziekenhuis StichtingPancreatic cancer
Start: 2024-09-18Target: 100Updated: 2024-07-09
Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; PERISCOPE-2
Active, not recruitingCTIS2023-510159-53-01
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichtingperitoneal dissemination in stomach cancer patients
Start: 2017-09-28Target: 226Updated: 2025-01-22

Phase 3

A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)
WithdrawnCTIS2022-502043-35-00
AstraZeneca ABAdvanced Biliary Tract Cancers
Target: 76Updated: 2023-09-04
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)
Active, not recruitingCTIS2022-502043-35-01
AstraZeneca ABAdvanced Biliary Tract Cancers
Start: 2024-04-24Target: 76Updated: 2025-11-26
COLLISION RELAPSE trial Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvant systemic therapy, a phase III prospective randomized controlled trial
Not yet recruitingCTIS2024-515341-41-01
Stichting Amsterdam UMCColorectal liver metastases
Target: 360Updated: 2024-12-11